# Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

Study · id `cardio:ct-nct01913847` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01913847](<https://clinicaltrials.gov/study/NCT01913847>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01913847

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 144 participants.

## Technical summary

Registry record NCT01913847. Randomized; triple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 144 participants (planned count; ClinicalTrials.gov record NCT01913847, source copy `cardio:ctgov-nct01913847-2017-11-27`, retrieved 2026-10-31)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01913847, source copy `cardio:ctgov-nct01913847-2017-11-27`, retrieved 2026-10-31)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT01913847, source copy `cardio:ctgov-nct01913847-2017-11-27`, retrieved 2026-10-31)
- Completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT01913847, source copy `cardio:ctgov-nct01913847-2017-11-27`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT01913847, source copy `cardio:ctgov-nct01913847-2017-11-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01913847-2017-11-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
- Condition: Pulmonary Hypertension
- Condition: Systolic Dysfunction
- Intervention (Drug): Sildenafil
- Intervention (Drug): Placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 540b6ea0fe3aab3eeabdcd3958b4979b6867d2f5171968316d2d19894590d246
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
